Fierce Biotech

ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug

Bristol Myers Squibb Chief Medical Officer Cristian Massacesi, M.D., has told Fierce that the latest data for its ...
Fierce Biotech

ESMO: AstraZeneca exec insists phase 3 ADC data ‘robust’ enough for regulators despite PFS miss

AstraZeneca executives were adamant that detailed data from a phase 3 study of the pharma’s next-generation antibody-drug ...
Fierce Biotech

ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals

Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. | Roche has shed more light on its investigational KRAS ...
Fierce Biotech

ESMO: J&J exec says RIPTAC readout is ‘best data we’ve ever seen’ for a prostate cancer drug

The Big Pharma has already launched a phase 2 trial of JNJ-6143 at a 50 mg daily dose in around 100 patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced ...
Fierce Biotech

‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data

Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...
Fierce Biotech

ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space

Eli Lilly has shared phase 1 data on an antibody-drug conjugate (ADC) in platinum-sensitive ovarian cancer (PSOC), shedding light on the company’s chances of competing for a market targeted by rivals ...
Fierce Biotech

Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde

Gilead has struck a deal to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program for $1.275 billion, positioning itself as a would-be challenger to Johnson & Johnson’s Icotyde across a ...
Fierce Biotech

ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra

Boehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra that entered phase 3 this year. | Boehringer Ingelheim ...
Fierce Biotech

Bolt makes inflammation play with Prana reverse merger, $120M financing

Bolt Biotherapeutics is acquiring Prana Therapies in a stock-for-stock reverse merger aimed at advancing Prana’s pipeline of antibodies targeting inflammatory conditions. | Bolt Biotherapeutics is ...
Fierce Biotech

ESMO: Takeda’s $1B bet ‘absolutely’ pays off with ADC ph. 3 win

Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) demonstrating overall survival (OS) of 10.2 months in tough to treat ...
Fierce Biotech

Chutes & Ladders—Troubled CSL enlists GSK vet Deborah Waterhouse to lead

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Fierce Biotech

BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up

| Pathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two companies signed a cutting-edge Alzheimer's disease-focused collaboration.